Analysts Set Intellia Therapeutics Inc (NASDAQ:NTLA) Price Target at $21.75
Shares of Intellia Therapeutics Inc (NASDAQ:NTLA) have received a consensus rating of “Buy” from the ten brokerages that are presently covering the company, MarketBeat reports. Five analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $24.00.
NTLA has been the subject of several recent analyst reports. Chardan Capital reaffirmed a “buy” rating on shares of Intellia Therapeutics in a research note on Thursday, August 6th. Goldman Sachs Group initiated coverage on Intellia Therapeutics in a research note on Friday. They set a “buy” rating and a $33.00 target price for the company. Zacks Investment Research cut Intellia Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Wedbush raised their target price on Intellia Therapeutics from $16.00 to $20.00 and gave the stock a “neutral” rating in a research note on Monday, June 1st. Finally, BidaskClub raised Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th.
Shares of NTLA traded up $1.10 during mid-day trading on Friday, reaching $23.55. 65,660 shares of the company were exchanged, compared to its average volume of 826,887. Intellia Therapeutics has a 52 week low of $9.18 and a 52 week high of $25.56. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.55 and a current ratio of 7.55. The stock has a market capitalization of $1.32 billion, a PE ratio of -10.33 and a beta of 1.69. The business has a 50 day simple moving average of $19.85 and a two-hundred day simple moving average of $17.59.
In other Intellia Therapeutics news, CEO John M. Leonard sold 5,000 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $21.83, for a total transaction of $109,150.00. Following the transaction, the chief executive officer now directly owns 472,352 shares in the company, valued at approximately $10,311,444.16. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Jose E. Rivera sold 5,615 shares of the firm’s stock in a transaction on Wednesday, July 15th. The shares were sold at an average price of $22.70, for a total value of $127,460.50. The disclosure for this sale can be found here. Insiders have sold 26,845 shares of company stock valued at $581,815 in the last quarter. 5.10% of the stock is currently owned by corporate insiders.
Large investors have recently modified their holdings of the business. Two Sigma Advisers LP lifted its stake in Intellia Therapeutics by 10.8% during the 1st quarter. Two Sigma Advisers LP now owns 256,917 shares of the company’s stock valued at $3,142,000 after acquiring an additional 25,000 shares in the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of Intellia Therapeutics by 290.6% during the 1st quarter. BNP Paribas Arbitrage SA now owns 20,876 shares of the company’s stock worth $255,000 after purchasing an additional 15,532 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Intellia Therapeutics by 77.7% during the 1st quarter. JPMorgan Chase & Co. now owns 223,622 shares of the company’s stock worth $2,735,000 after purchasing an additional 97,807 shares during the period. Ameritas Investment Company LLC bought a new stake in shares of Intellia Therapeutics during the 1st quarter worth $31,000. Finally, Point72 Asset Management L.P. bought a new stake in shares of Intellia Therapeutics during the 2nd quarter worth $18,306,000. Institutional investors and hedge funds own 91.79% of the company’s stock.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.
Featured Article: What are the risks of holding treasury bonds?
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.